CliffBio
small molecule

CALDOLOR

IBUPROFEN

Loss of exclusivityMarch 2032latest FDA-listed patent expiry
CompanyCumberland →See this company's full patent-cliff portfolio

Drug detail

Brand nameCALDOLOR
Active ingredientIBUPROFEN
Strength800MG/8ML (100MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJune 2009
Marketing statusRX

Listed patents

PatentExpiresType
11806400March 2032use U-3746
9012508September 2030use U-981
9649284September 2029use U-2018
8871810September 2029use U-981
9295639September 2029use U-1756
9114068September 2029use U-1735
9138404September 2029use U-1756
8735452September 2029use U-981

Regulatory exclusivity

CodeExpires
NPPMay 2026

More from Cumberland

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CALDOLOR patent cliff — loss of exclusivity March 2032 | CliffBio